Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma

BACKGROUND: Nivolumab is approved for patients with metastatic renal cell carcinoma (mRCC) refractory to prior antiangiogenic therapy. The clinical activity of nivolumab in patients with non-clear cell RCC subtypes remains unknown as these patients were excluded from the original nivolumab trials. M...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Koshkin, Vadim S., Barata, Pedro C., Zhang, Tian, George, Daniel J., Atkins, Michael B., Kelly, William J., Vogelzang, Nicholas J., Pal, Sumanta K., Hsu, JoAnn, Appleman, Leonard J., Ornstein, Moshe C., Gilligan, Timothy, Grivas, Petros, Garcia, Jorge A., Rini, Brian I.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5789686/
https://ncbi.nlm.nih.gov/pubmed/29378660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0319-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados